LuxMare is a project completed this year by architecture office Mário Martins Atelier and which consists of two contemporary houses that complement one another while managing to maintain their ...

The Boston Red Sox surprised everyone when they signed Ranger Suarez, after missing on Pete Alonso and letting Alex Bregman walk in free agency. Now, they need to make one last move to appease their ...

Texas is setting up to have a high-powered rushing attack in 2026, as top transfer portal running back Raleek Brown is reportedly sticking to his commitment to the Longhorns even after Texas added ...

CGDV is branded as the Capital Group's "Dividend Value" ETF, but a quick glance at its strategy, holdings, and fundamentals reveals that it's neither dividend- nor value-oriented. Still, that's not an ...

A nearly intact Geran-2, landed upright on the ground, was found with a 9K333 Verba Man-Portable Air Defense System (MANPADS) mounted on the top. A month after a Russian Geran-2 one-way attack (OWA) ...

GREEN BAY, Wis. (WSAW) - The Packers have added a two-time Pro Bowler to their defensive unit, reuniting Micah Parsons with former teammate Trevon Diggs. Diggs led the NFL with 11 interceptions in the ...

Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges. Neither ...

Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges. Broader ...

ETFs offer a convenient way for investors to gain broad, diversified exposure to stocks. It's hard to beat Vanguard's S&P 500 ETF, which has delivered excellent results over time. Vanguard's ...

The Wisconsin Badgers win over the Marquette Golden Eagles offered more than bragging rights within the state. It gave the Badgers a clearer understanding of who they are and what they can become as ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...